Cargando…
Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden
Background. Despite recognized risks associated with hyperphosphataemia in patients with chronic kidney disease (CKD) Stage 5 on dialysis, the achievement of target levels of serum phosphate is poor. It is likely that this is partly due to poor adherence by patients to their phosphate-binder treatme...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2568007/ https://www.ncbi.nlm.nih.gov/pubmed/18577536 http://dx.doi.org/10.1093/ndt/gfn310 |